Effect of Population Size and Mutation Rate on the Evolution of RNA Sequences on an Adaptive Landscape Determined by RNA Folding.

The dynamics of populations evolving on an adaptive landscape depends on multiple factors, including the structure of the landscape, the rate of mutations, and effective population size. Existing theoretical work often makes ad hoc and simplifying assumptions about landscape structure, whereas experimental work can vary important parameters only to a limited extent. We here overcome some of these limitations by simulating the adaptive evolution of RNA molecules, whose fitness is determined by the thermodynamics of RNA secondary structure folding. We study the influence of mutation rates and population sizes on final mean population fitness, on the substitution rates of mutations, and on population diversity. We show that evolutionary dynamics cannot be understood as a function of mutation rate µ, population size N, or population mutation rate Nµ alone. For example, at a given mutation rate, clonal interference prevents the fixation of beneficial mutations as population size increases, but larger populations still arrive at a higher mean fitness. In addition, at the highest population mutation rates we study, mean final fitness increases with population size, because small populations are driven to low fitness by the relatively higher incidence of mutations they experience. Our observations show that mutation rate and population size can interact in complex ways to influence the adaptive dynamics of a population on a biophysically motivated fitness landscape

Investigations of the unsteady aerodynamic characteristics for intakes at crosswind

The ground vortex generated in front of an intake operating near the ground and subjected to crosswind is investigated using CFD and compared to the experiments. The flow field of a scale-model intake is numerically simulated with both steady and unsteady approach, with the aim of predicting ground vortex effects and to characterize the vortex unsteady behaviour. The experimental results showed that for an intake near the ground under crosswind the ground vortex that forms under the intake and the in-duct separation, when present, exhibit unsteady behaviour that becomes stronger as the crosswind velocity is increased. The simulations indicate that a steady-state approach only partially reproduces the time-averaged ground vortex characteristics and in-duct distortion losses, while an unsteady approach shows a lower level of unsteadiness compared to the experimental observations. The consequences of the unsteady flow in the intake on the fan aerodynamic and aeroelastic stability are finally discussed to reinforce that these can result in significant non-synchronous vibration (NSV) and loss of stall margin which cannot be adequately assessed if no unsteady component of the inlet distortions is taken into account

Requirements Analysis for an Open Research Knowledge Graph

Current science communication has a number of drawbacks and bottlenecks which have been subject of discussion lately: Among others, the rising number of published articles makes it nearly impossible to get an overview of the state of the art in a certain field, or reproducibility is hampered by fixed-length, document-based publications which normally cannot cover all details of a research work. Recently, several initiatives have proposed knowledge graphs (KGs) for organising scientific information as a solution to many of the current issues. The focus of these proposals is, however, usually restricted to very specific use cases. In this paper, we aim to transcend this limited perspective by presenting a comprehensive analysis of requirements for an Open Research Knowledge Graph (ORKG) by (a) collecting daily core tasks of a scientist, (b) establishing their consequential requirements for a KG-based system, (c) identifying overlaps and specificities, and their coverage in current solutions. As a result, we map necessary and desirable requirements for successful KG-based science communication, derive implications and outline possible solutions.Comment: Accepted for publishing in 24th International Conference on Theory and Practice of Digital Libraries, TPDL 202

A positron emission tomography imaging study to confirm target engagement in the lungs of patients with idiopathic pulmonary fibrosis following a single dose of a novel inhaled αvβ6 integrin inhibitor

© 2020 The Author(s). Background: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease with poor prognosis and a significant unmet medical need. This study evaluated the safety, pharmacokinetics (PK) and target engagement in the lungs, of GSK3008348, a novel inhaled alpha-v beta-6 (αvβ6) integrin inhibitor, in participants with IPF. Methods: This was a phase 1b, randomised, double-blind (sponsor unblind) study, conducted in the UK (two clinical sites, one imaging unit) between June 2017 and July 2018 (NCT03069989). Participants with a definite or probable diagnosis of IPF received a single nebulised dose of 1000 mcg GSK3008348 or placebo (ratio 5:2) in two dosing periods. In period 1, safety and PK assessments were performed up to 24 h post-dose; in period 2, after a 7-day to 28-day washout, participants underwent a total of three positron emission tomography (PET) scans: Baseline, Day 1 (~ 30 min post-dosing) and Day 2 (~ 24 h post-dosing), using a radiolabelled αvβ6-specific ligand, [18F]FB-A20FMDV2. The primary endpoint was whole lung volume of distribution (VT), not corrected for air volume, at ~ 30 min post-dose compared with pre-dose. The study success criterion, determined using Bayesian analysis, was a posterior probability (true % reduction in VT > 0%) of ≥80%. Results: Eight participants with IPF were enrolled and seven completed the study. Adjusted posterior median reduction in uncorrected VT at ~ 30 min after GSK3008348 inhalation was 20% (95% CrI:-9 to 42%). The posterior probability that the true % reduction in VT > 0% was 93%. GSK3008348 was well tolerated with no reports of serious adverse events or clinically significant abnormalities that were attributable to study treatment. PK was successfully characterised showing rapid absorption followed by a multiphasic elimination. Conclusions: This study demonstrated engagement of the αvβ6 integrin target in the lung following nebulised dosing with GSK3008348 to participants with IPF. To the best of our knowledge this is the first time a target-specific PET radioligand has been used to assess target engagement in the lung, not least for an inhaled drug. Trial registration: Clinicaltrials.gov: NCT03069989; date of registration: 3 March 2017

Expression of hereditary hemochromatosis C282Y HFE protein in HEK293 cells activates specific endoplasmic reticulum stress responses

<p>Abstract</p> <p>Background</p> <p>Hereditary Hemochromatosis (HH) is a genetic disease associated with iron overload, in which individuals homozygous for the mutant C282Y <it>HFE </it>associated allele are at risk for the development of a range of disorders particularly liver disease. Conformational diseases are a class of disorders associated with the expression of misfolded protein. HFE C282Y is a mutant protein that does not fold correctly and consequently is retained in the Endoplasmic Reticulum (ER). In this context, we sought to identify ER stress signals associated with mutant C282Y HFE protein expression, which may have a role in the molecular pathogenesis of HH.</p> <p>Results</p> <p>Vector constructs of Wild type HFE and Mutant C282Y HFE were made and transfected into HEK293 cell lines. We have shown that expression of C282Y HFE protein triggers both an unfolded protein response (UPR), as revealed by the increased GRP78, ATF6 and CHOP expression, and an ER overload response (EOR), as indicated by NF-κB activation. Furthermore, C282Y HFE protein induced apoptotic responses associated with activation of ER stress. Inhibition studies demonstrated that tauroursodeoxycholic acid, an endogenous bile acid, downregulates these events. Finally, we found that the co-existence of both C282Y HFE and Z alpha 1-antitrypsin protein (the protein associated with the liver disease of Z alpha 1-antitrypsin deficiency) expression on ER stress responses acted as potential disease modifiers with respect to each other.</p> <p>Conclusion</p> <p>Our novel observations suggest that both the ER overload response (EOR) and the unfolded protein response (UPR) are activated by mutant C282Y HFE protein.</p

Ancient chicken remains reveal the origins of virulence in Marek's disease virus

This is the author accepted manuscript. The final version is available from the American Association for the Advancement of Science via the DOI in this recordData and materials availability: All MDV sequence data generated have been deposited in GenBank under accession PRJEB64489. Code is available at GitHub (https://github.com/antonisdim/MDV) and archived at Zenodo (https://zenodo.org/records/10022436) (25).The pronounced growth in livestock populations since the 1950s has altered the epidemiological and evolutionary trajectory of their associated pathogens. For example, Marek's disease virus (MDV), which causes lymphoid tumors in chickens, has experienced a marked increase in virulence over the past century. Today, MDV infections kill >90% of unvaccinated birds, and controlling it costs more than US$1 billion annually. By sequencing MDV genomes derived from archeological chickens, we demonstrate that it has been circulating for at least 1000 years. We functionally tested the Meq oncogene, one of 49 viral genes positively selected in modern strains, demonstrating that ancient MDV was likely incapable of driving tumor formation. Our results demonstrate the power of ancient DNA approaches to trace the molecular basis of virulence in economically relevant pathogens.European Research Council (ERC)Wellcome TrustOxford Martin School Pandemic Genomics ProgrammeArts and Humanities Research Council (AHRC)European Union Horizon 2020Biotechnology and Biological Sciences Research Council (BBSRC)Research Foundation–Flanders (Fonds voor Wetenschappelijk Onderzoek

Assessment of protein silver nanoparticles toxicity against pathogenic Alternaria solani

Mycogenic synthesis of silver nanoparticles (AgNPs) was carried out in the present investigation using an aqueous extract of endophytic non-pathogenic Alternaria solani F10 (KT721914). The mycosynthesized AgNPs were characterized by means of spectroscopic and microscopic techniques. The surface plasmon resonance found at 430 nm confirmed the formation of stable AgNPs for several weeks at room temperature. Also, the results revealed the formation of spherical and monodispersed AgNPs with an average size of 14.8 +/- 1.2 nm. The FT-IR spectrum suggested that the fungal extracellular proteins and secondary metabolites had the role in Ag reduction and AgNPs capping of which protein Ag nanoconjugates were formed. Furthermore, the mycosynthesized AgNPs exhibited potent antifungal activity against different pathogenic isolates of the same Alternaria solani fungus, the causal pathogen of tomato early blight disease. The antifungal efficiency of the AgNPs at 1, 5 and 10 ppm were evaluated for 8 days after incubation by measuring the inhibition rate of fungal radial growth. The results were further supported by investigating fungal hyphae morphology alteration by scanning and transmission electron microscopy. Treated fungal hyphae showed formation of pits and pores. Also, the mycosynthesized AgNPs were able to pass and distribute throughout the fungal cell area and interact with the cell components.A financial support from European Commission by Erasmus Mundus Scholarship-ACTION 2 WELCOME program is gratefully acknowledged. Work in JAD laboratory was supported by grant BIO2014-54269-R from the Ministerio de Economia y Competividad (Spain).Abdel-Hafez, SII.; Nafady, NA.; Abdel-Rahim, IR.; Shaltout, AM.; Daros Arnau, JA.; Mohamed, MA. (2016). Assessment of protein silver nanoparticles toxicity against pathogenic Alternaria solani. 3 Biotech. 6(199):1-12. https://doi.org/10.1007/s13205-016-0515-6S1126199Abd-Alla MH, Nafady NA, Khalaf DM (2016) Assessment of silver nanoparticles contamination on faba bean-Rhizobium leguminosarum bv. viciae-Glomus aggregatum symbiosis: implications for induction of autophagy process in root nodule. Agric Ecosyst Environ 15(218):163–177Abdel-Hafez SI, Nafady NA, Abdel-Rahim IR, Shaltout AM, Mohamed MA (2016) Biogenesis and optimisation of silver nanoparticles by the endophytic fungus cladosporium sphaerospermum. Int J Nano Chem 2(1):11–19Agrios GN (1997) Plant pathology, 4th edn. Academic Press, LondonAzizi S, Namvar F, Mahdavi M, Ahmad MB, Mohamad R (2013) Biosynthesis of silver nanoparticles using brown marine macroalga, Sargassum muticum aqueous extract. Materials 6(12):5942–5950Birla S, Tiwari V, Gade A, Ingle A, Yadav A, Rai M (2009) Fabrication of silver nanoparticles by Phoma glomerala and its combined effect against Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus. Lett Appl Microbiol 48(2):173–179Chohan S, Perveen R, Mehmood MA, Naz S, Akram N (2015) Morpho-physiological studies, management and screening of tomato germplasm against alternaria solani, the causal agent of tomato early blight. Int J Agric Biol 17(1):111–118Das VL, Thomas R, Varghese RT, Soniya EV, Mathew J, Radhakrishnan EK (2014) Extracellular synthesis of silver nanoparticles by the Bacillus strain CS 11 isolated from industrialized area. 3 Biotech 4(2):121–126Datar VV, Mayee CD (1981) Assessment of losses in tomato yield due to early blight. Indian phytopathol 34:191–195Elyasi M, Khalilzadeh MA, Karimi-Maleh H (2013) High sensitive voltammetric sensor based on Pt/CNTs nanocomposite modified ionic liquid carbon paste electrode for determination of Sudan I in food samples. Food Chem 141(4):4311–4317Ensafi AA, Karimi-Maleh H (2010) Modified multiwall carbon nanotubes paste electrode as a sensor for simultaneous determination of 6-thioguanine and folic acid using ferrocenedicarboxylic acid as a mediator. J Electroanal Chem 640(1):75–83Fayaz M, Tiwary CS, Kalaichelvan PT, Venkatesan R (2010) Blue orange light emission from biogenic synthesized silver nanoparticles using Trichoderma viride. Colloids Surf B Biointerfaces 75(1):175–178Gardes M, Bruns TD (1993) ITS primers with enhanced specificity for basidiomycetes-application to the identification of mycorrhizae and rusts. Mol Ecol 2(2):113–118Gurunathan S, Lee KJ, Kalishwaralal K, Sheikpranbabu S, Vaidyanathan R, Eom SH (2009) Antiangiogenic properties of silver nanoparticles. Biomaterials 30(31):6341–6350Kagithoju S, Godishala V, Nanna RS (2015) Eco-friendly and green synthesis of silver nanoparticles using leaf extract of Strychnos potatorum Linn. F. and their bactericidal activities. 3 Biotech 5(5):709–714Kanmani P, Lim ST (2013) Synthesis and structural characterization of silver nanoparticles using bacterial exopolysaccharide and its antimicrobial activity against food and multidrug resistant pathogens. Process Biochem 48(7):1099–1106Khan MR, Rizvi TF (2014) Nanotechnology: scope and application in plant disease management. Plant Pathol J 13:214–231Khan M, Rizwani GH, Shareef H, Cavar S, Zia-Ul-Haq M (2013) Assessment of total phenolic content and antioxidant potential of methanol extract of Peltophorum pterocarpum (DC.) Backer ex K. Heyne. Pak J Pharm Sci 26(5):967–972Kim KJ, Sung WS, Suh BK, Moon SK, Choi JS, Kim JG, Lee DG (2009a) Antifungal activity and mode of action of silver nano-particles on Candida albicans. Biometals 22(2):235–242Kim SW, Kim KS, Lamsal K, Kim YJ, Kim SB, Jung M, Sim SJ, Kim HS, Chang SJ, Kim JK, Lee YS (2009b) An in vitro study of the antifungal effect of silver nanoparticles on oak wilt pathogen Raffaelea sp. J Microbiol Biotechnol 19(8):760–764Kim SW, Jung JH, Lamsal K, Kim YS, Min JS, Lee YS (2012) Antifungal effects of silver nanoparticles (AgNPs) against various plant pathogenic fungi. Mycobiology 40(1):53–58Kirk AB, Martinelango PK, Tian K, Dutta A, Smith EE, Dasgupta PK (2005) Perchlorate and iodide in dairy and breast milk. Environ Sci Technol 39(7):2011–2017Kumar CG, Sujitha P (2014) Green synthesis of Kocuran-functionalized silver glyconanoparticles for use as antibiofilm coatings on silicone urethral catheters. Nanotechnology 25(32):325101Liu L, Yang J, Xie J, Luo Z, Jiang J, Yang YY, Liu S (2013) The potent antimicrobial properties of cell penetrating peptide-conjugated silver nanoparticles with excellent selectivity for Gram-positive bacteria over erythrocytes. Nanoscale 5(9):3834–3840Loza K, Diendorf J, Sengstock C, Ruiz-Gonzalez L, Gonzalez-Calbet J, Vallet- Regi M, Köller M, Epple M (2014) The dissolution and biological effects of silver nanoparticles in biological media. J Mater Chem B 2:1634–1643Malik P, Shankar R, Malik V, Sharma N, Mukherjee TK (2014) Green chemistry based benign routes for nanoparticle synthesis. J Nanopart 24:1–14McDonnell G, Russell AD (2001) Antiseptics and disinfectants: activity, action, and resistance. Clin Microbiol Rev 14(1):227Metuku RP, Pabba S, Burra S, Gudikandula K, Charya MS (2014) Biosynthesis of silver nanoparticles from Schizophyllum radiatum HE 863742.1: their characterization and antimicrobial activity. 3 Biotech 4(3):227–234Mohamed AM (2015) One-step functionalization of silver Nanoparticles using the orsellinic acid compound isolated from the endophytic fungus Epicoccum Nigrum: characterization and antifungal activity. Int J Nano Chem. 1(3):103–110Moradi R, Sebt SA, Karimi-Maleh H, Sadeghi R, Karimi F, Bahari A, Arabi H (2013) Synthesis and application of FePt/CNTs nanocomposite as a sensor and novel amide ligand as a mediator for simultaneous determination of glutathione, nicotinamide adenine dinucleotide and tryptophan. Phys Chem Chem Phys 15(16):5888–5897Nadworny PL, Wang J, Tredget EE, Burrell RE (2008) Anti-inflammatory activity of nanocrystalline silver in a porcine contact dermatitis model. Nanomedicine 4(3):241–251Namanda S, Olanya OM, Adipala E, Hakiza JJ, El-Bedewy R, Baghsari AS, Ewell P (2004) Fungicide application and host-resistance for potato late blight management: benefits assessment from on-farm studies in SW Uganda. Crop Prot 23(11):1075–1083Narayanan KB, Sakthivel N (2010) Biological synthesis of metal nanoparticles by microbes. Adv Colloid Interface Sci 156(1):1–3Netala VR, Kotakadi VS, Bobbu P, Gaddam SA, Tartte V (2016) Endophytic fungal isolate mediated biosynthesis of silver nanoparticles and their free radical scavenging activity and anti microbial studies. 3 Biotech 6(2):1–9Petrini O, Fisher PJ (1988) A comparative study of fungal endophytes in xylem and whole stems of Pinus sylvestris and Fagus sylvatica. Trans Br Mycol Soc 91(2):233–238Qin Y, Ji X, Jing J, Liu H, Wu H, Yang W (2010) Size control over spherical silver nanoparticles by ascorbic acid reduction. Colloids Surf A Physicochem Eng Asp 372(1):172–176Ramamurthy CH, Padma M, Mareeswaran R, Suyavaran A, Kumar MS, Premkumar K, Thirunavukkarasu C (2013) The extra cellular synthesis of gold and silver nanoparticles and their free radical scavenging and antibacterial properties. Colloids Surf B Biointerfaces 102:808–815Rogers JV, Parkinson CV, Choi YW, Speshock JL, Hussain SM (2008) A preliminary assessment of silver nanoparticle inhibition of monkeypox virus plaque formation. Nanoscale Res Lett 3(4):129–133Sadeghi R, Karimi-Maleh H, Khalilzadeh MA, Beitollahi H, Ranjbarha Z, Zanousi MB (2013) A new strategy for determination of hydroxylamine and phenol in water and waste water samples using modified nanosensor. Environ Sci Pollut Res Int 20(9):6584–6593Saharan V, Sharma G, Yadav M, Choudhary MK, Sharma SS, Pal A, Biswas P (2015) Synthesis and in vitro antifungal efficacy of Cu–chitosan nanoparticles against pathogenic fungi of tomato. Int J Biol Macromolec 75:346–353Satyavani K, Ramanathan T, Gurudeeban S (2011) Plant mediated synthesis of biomedical silver nanoparticles by using leaf extract of Citrullus colocynthis. R J Nanosci Nanotech 1(2):95–101Siddique YH, Fatima A, Jyoti S, Naz F, Khan W, Singh BR, Naqvi AH (2013) Evaluation of the toxic potential of graphene copper nanocomposite (GCNC) in the third instar larvae of transgenic Drosophila melanogaster (hsp70-lacZ) Bg 9. PloS one 8(12):e80944Stoimenov PK, Klinger RL, Marchin GL, Klabunde KJ (2002) Metal oxide nanoparticles as bactericidal agents. Langmuir 18(17):6679–6686Tanvir S, Oudet F, Pulvin S, Anderson WA (2012) Coenzyme based synthesis of silver nanocrystals. Enzyme Microb Technol 51(4):231–236Thakkar KN, Mhatre SS, Parikh RY (2010) Biological synthesis of metallic nanoparticles. Nanomedicine 6(2):257–262Vahdati AR, Sadeghi B (2013) A study on the assessment of DNA strand-breaking activity by silver and silica nanoparticles. J Nanostruct Chem 1:1–3Wu D, Fan W, Kishen A, Gutmann JL, Fan B (2014) Evaluation of the antibacterial efficacy of silver nanoparticles against Enterococcus faecalis biofilm. J Endod 40:285–290Zachariadis PC, Hadjikakou SK, Hadjiliadis N, Skoulika S, Michaelides A, Balzarini J, De Clercq E (2004) Synthesis, characterization and in vitro study of the cytostatic and antiviral activity of new polymeric silver (I) complexes with ribbon structures derived from the conjugated heterocyclic thioamide 2-mercapto-3, 4, 5, 6-tetra-hydropyrimidine. Eur J Inorg Chem 7:1420–1426Zhang W, Qiao X, Chen J (2007) Synthesis of silver nanoparticles—effects of concerned parameters in water/oil microemulsion. Mater Sci Eng, B 142(1):1–5Zhao N, Gao J, Enns CA, Knutson MD (2010) ZRT/IRT-like protein 14 (ZIP14) promotes the cellular assimilation of iron from transferrin. J Biol Chem 285(42):32141–3215

Burden of disease scenarios for 204 countries and territories, 2022–2050: a forecasting analysis for the Global Burden of Disease Study 2021

Background: Future trends in disease burden and drivers of health are of great interest to policy makers and the public at large. This information can be used for policy and long-term health investment, planning, and prioritisation. We have expanded and improved upon previous forecasts produced as part of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) and provide a reference forecast (the most likely future), and alternative scenarios assessing disease burden trajectories if selected sets of risk factors were eliminated from current levels by 2050. Methods: Using forecasts of major drivers of health such as the Socio-demographic Index (SDI; a composite measure of lag-distributed income per capita, mean years of education, and total fertility under 25 years of age) and the full set of risk factor exposures captured by GBD, we provide cause-specific forecasts of mortality, years of life lost (YLLs), years lived with disability (YLDs), and disability-adjusted life-years (DALYs) by age and sex from 2022 to 2050 for 204 countries and territories, 21 GBD regions, seven super-regions, and the world. All analyses were done at the cause-specific level so that only risk factors deemed causal by the GBD comparative risk assessment influenced future trajectories of mortality for each disease. Cause-specific mortality was modelled using mixed-effects models with SDI and time as the main covariates, and the combined impact of causal risk factors as an offset in the model. At the all-cause mortality level, we captured unexplained variation by modelling residuals with an autoregressive integrated moving average model with drift attenuation. These all-cause forecasts constrained the cause-specific forecasts at successively deeper levels of the GBD cause hierarchy using cascading mortality models, thus ensuring a robust estimate of cause-specific mortality. For non-fatal measures (eg, low back pain), incidence and prevalence were forecasted from mixed-effects models with SDI as the main covariate, and YLDs were computed from the resulting prevalence forecasts and average disability weights from GBD. Alternative future scenarios were constructed by replacing appropriate reference trajectories for risk factors with hypothetical trajectories of gradual elimination of risk factor exposure from current levels to 2050. The scenarios were constructed from various sets of risk factors: environmental risks (Safer Environment scenario), risks associated with communicable, maternal, neonatal, and nutritional diseases (CMNNs; Improved Childhood Nutrition and Vaccination scenario), risks associated with major non-communicable diseases (NCDs; Improved Behavioural and Metabolic Risks scenario), and the combined effects of these three scenarios. Using the Shared Socioeconomic Pathways climate scenarios SSP2-4.5 as reference and SSP1-1.9 as an optimistic alternative in the Safer Environment scenario, we accounted for climate change impact on health by using the most recent Intergovernmental Panel on Climate Change temperature forecasts and published trajectories of ambient air pollution for the same two scenarios. Life expectancy and healthy life expectancy were computed using standard methods. The forecasting framework includes computing the age-sex-specific future population for each location and separately for each scenario. 95% uncertainty intervals (UIs) for each individual future estimate were derived from the 2·5th and 97·5th percentiles of distributions generated from propagating 500 draws through the multistage computational pipeline. Findings: In the reference scenario forecast, global and super-regional life expectancy increased from 2022 to 2050, but improvement was at a slower pace than in the three decades preceding the COVID-19 pandemic (beginning in 2020). Gains in future life expectancy were forecasted to be greatest in super-regions with comparatively low life expectancies (such as sub-Saharan Africa) compared with super-regions with higher life expectancies (such as the high-income super-region), leading to a trend towards convergence in life expectancy across locations between now and 2050. At the super-region level, forecasted healthy life expectancy patterns were similar to those of life expectancies. Forecasts for the reference scenario found that health will improve in the coming decades, with all-cause age-standardised DALY rates decreasing in every GBD super-region. The total DALY burden measured in counts, however, will increase in every super-region, largely a function of population ageing and growth. We also forecasted that both DALY counts and age-standardised DALY rates will continue to shift from CMNNs to NCDs, with the most pronounced shifts occurring in sub-Saharan Africa (60·1% [95% UI 56·8–63·1] of DALYs were from CMNNs in 2022 compared with 35·8% [31·0–45·0] in 2050) and south Asia (31·7% [29·2–34·1] to 15·5% [13·7–17·5]). This shift is reflected in the leading global causes of DALYs, with the top four causes in 2050 being ischaemic heart disease, stroke, diabetes, and chronic obstructive pulmonary disease, compared with 2022, with ischaemic heart disease, neonatal disorders, stroke, and lower respiratory infections at the top. The global proportion of DALYs due to YLDs likewise increased from 33·8% (27·4–40·3) to 41·1% (33·9–48·1) from 2022 to 2050, demonstrating an important shift in overall disease burden towards morbidity and away from premature death. The largest shift of this kind was forecasted for sub-Saharan Africa, from 20·1% (15·6–25·3) of DALYs due to YLDs in 2022 to 35·6% (26·5–43·0) in 2050. In the assessment of alternative future scenarios, the combined effects of the scenarios (Safer Environment, Improved Childhood Nutrition and Vaccination, and Improved Behavioural and Metabolic Risks scenarios) demonstrated an important decrease in the global burden of DALYs in 2050 of 15·4% (13·5–17·5) compared with the reference scenario, with decreases across super-regions ranging from 10·4% (9·7–11·3) in the high-income super-region to 23·9% (20·7–27·3) in north Africa and the Middle East. The Safer Environment scenario had its largest decrease in sub-Saharan Africa (5·2% [3·5–6·8]), the Improved Behavioural and Metabolic Risks scenario in north Africa and the Middle East (23·2% [20·2–26·5]), and the Improved Nutrition and Vaccination scenario in sub-Saharan Africa (2·0% [–0·6 to 3·6]). Interpretation: Globally, life expectancy and age-standardised disease burden were forecasted to improve between 2022 and 2050, with the majority of the burden continuing to shift from CMNNs to NCDs. That said, continued progress on reducing the CMNN disease burden will be dependent on maintaining investment in and policy emphasis on CMNN disease prevention and treatment. Mostly due to growth and ageing of populations, the number of deaths and DALYs due to all causes combined will generally increase. By constructing alternative future scenarios wherein certain risk exposures are eliminated by 2050, we have shown that opportunities exist to substantially improve health outcomes in the future through concerted efforts to prevent exposure to well established risk factors and to expand access to key health interventions